Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Operating Leases (2020 - 2024)

Mereo BioPharma (MREO) has disclosed Operating Leases for 5 consecutive years, with $187000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Operating Leases fell 79.36% to $187000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $187000.0, a 79.36% decrease, with the full-year FY2024 number at $187000.0, down 79.36% from a year prior.
  • Operating Leases was $187000.0 for Q4 2024 at Mereo BioPharma, down from $394000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $2.4 million in Q4 2021 to a low of $187000.0 in Q4 2024.
  • A 5-year average of $1.1 million and a median of $1.1 million in 2023 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: soared 54.63% in 2021, then crashed 79.36% in 2024.
  • Mereo BioPharma's Operating Leases stood at $1.5 million in 2020, then skyrocketed by 54.63% to $2.4 million in 2021, then tumbled by 37.45% to $1.5 million in 2022, then crashed by 38.74% to $906000.0 in 2023, then plummeted by 79.36% to $187000.0 in 2024.
  • Per Business Quant, the three most recent readings for MREO's Operating Leases are $187000.0 (Q4 2024), $394000.0 (Q3 2024), and $552000.0 (Q2 2024).